MX2007003433A - Sintesis de n-fluorobencil) -n- (1-metilpiperidin-4-il) -n'- (4- (2-metilpropiloxi) fenilmetil) carbamida y su sal de tartrato y formas cristalinas. - Google Patents

Sintesis de n-fluorobencil) -n- (1-metilpiperidin-4-il) -n'- (4- (2-metilpropiloxi) fenilmetil) carbamida y su sal de tartrato y formas cristalinas.

Info

Publication number
MX2007003433A
MX2007003433A MX2007003433A MX2007003433A MX2007003433A MX 2007003433 A MX2007003433 A MX 2007003433A MX 2007003433 A MX2007003433 A MX 2007003433A MX 2007003433 A MX2007003433 A MX 2007003433A MX 2007003433 A MX2007003433 A MX 2007003433A
Authority
MX
Mexico
Prior art keywords
methylpiperidin
fluorobenzyl
methylpropyloxy
carbamide
phenylmethyl
Prior art date
Application number
MX2007003433A
Other languages
English (en)
Spanish (es)
Inventor
Fritz Blatter
Nathalie Schlienger
Mikkel Thygesen
Jorg Berghausen
Bo-Ragnar Tolf
Carl-Mangus A Andersson
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35539440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007003433(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of MX2007003433A publication Critical patent/MX2007003433A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MX2007003433A 2004-09-27 2005-09-26 Sintesis de n-fluorobencil) -n- (1-metilpiperidin-4-il) -n'- (4- (2-metilpropiloxi) fenilmetil) carbamida y su sal de tartrato y formas cristalinas. MX2007003433A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61401404P 2004-09-27 2004-09-27
PCT/US2005/034813 WO2006037043A1 (en) 2004-09-27 2005-09-26 Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms

Publications (1)

Publication Number Publication Date
MX2007003433A true MX2007003433A (es) 2007-08-06

Family

ID=35539440

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2007003433A MX2007003433A (es) 2004-09-27 2005-09-26 Sintesis de n-fluorobencil) -n- (1-metilpiperidin-4-il) -n'- (4- (2-metilpropiloxi) fenilmetil) carbamida y su sal de tartrato y formas cristalinas.
MX2007003403A MX2007003403A (es) 2004-09-27 2005-09-26 Sales de n-(4-fluorobencil) -n-(1-metilpiperidin -4-il)-n??- (4-(2-metilpropiloxi) fenilmetil) carbamida y su preparacion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2007003403A MX2007003403A (es) 2004-09-27 2005-09-26 Sales de n-(4-fluorobencil) -n-(1-metilpiperidin -4-il)-n??- (4-(2-metilpropiloxi) fenilmetil) carbamida y su preparacion.

Country Status (17)

Country Link
US (6) US7868176B2 (https=)
EP (3) EP2289879B1 (https=)
JP (2) JP4996467B2 (https=)
KR (2) KR101260036B1 (https=)
CN (3) CN101031548B (https=)
AU (2) AU2005289635A1 (https=)
BR (1) BRPI0516063A (https=)
CA (2) CA2580136C (https=)
DK (1) DK1794126T3 (https=)
ES (2) ES2412207T3 (https=)
MX (2) MX2007003433A (https=)
NZ (1) NZ553702A (https=)
PL (2) PL2289879T3 (https=)
RU (2) RU2417986C2 (https=)
SG (2) SG157378A1 (https=)
WO (2) WO2006037043A1 (https=)
ZA (3) ZA200702345B (https=)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2002126554A (ru) * 2000-03-06 2004-03-20 Акадиа Фармасьютикалз, Инк. (Us) Азациклические соединения для применения при лечении опосредованных серотонином заболеваний
WO2003057698A2 (en) * 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Spiroazacyclic compounds as monoamine receptor modulators
CN100509804C (zh) 2002-06-24 2009-07-08 阿卡蒂亚药品公司 N-取代哌啶衍生物作为血清素受体试剂
US7253186B2 (en) * 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
PT1587789E (pt) 2003-01-16 2008-12-16 Acadia Pharm Inc Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
JP4996467B2 (ja) * 2004-09-27 2012-08-08 アカディア ファーマシューティカルズ インコーポレイテッド Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成
WO2007124136A1 (en) * 2006-04-19 2007-11-01 Acadia Pharmaceuticals, Inc. Use of 4-amino-piperidines for treating sleep disorders
EP2037918A2 (en) * 2006-05-15 2009-03-25 Acadia Pharmaceuticals Inc. Pharmaceutical formulations of pimavanserin
HRP20130713T1 (en) 2007-03-19 2013-09-30 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
WO2008141057A1 (en) * 2007-05-08 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea
AU2008254669A1 (en) * 2007-05-18 2008-11-27 Acadia Pharmaceuticals Inc. Use of pimavanserin in the treatment of parkinson and symptoms thereof
WO2009039461A2 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
JP2010540454A (ja) * 2007-09-21 2010-12-24 アカディア ファーマシューティカルズ，インコーポレーテッド ピマバンセリンと他の薬剤との併用投与
US20100029942A1 (en) * 2008-06-30 2010-02-04 Sergio Cesco-Cancian Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
AR091507A1 (es) * 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
US9446037B2 (en) 2012-11-27 2016-09-20 Acadia Pharmaceuticals Inc. Methods for the treatment of parkinson's disease psychosis using pimavanserin
US9630971B2 (en) * 2013-06-21 2017-04-25 Intra-Cellular Therapies, Inc. Free base crystals
JP2015117192A (ja) * 2013-12-17 2015-06-25 東和薬品株式会社 シロドシンγ型結晶及びその製造方法
CN104961671B (zh) * 2014-09-05 2018-01-02 苏州晶云药物科技有限公司 N‑(4‑氟苄基)‑n‑(1‑甲基哌啶‑4‑基)‑n’‑(4‑(2‑甲基丙氧基)‑苯基甲基)脲半酒石酸盐的晶型及其制备方法
WO2016141003A1 (en) 2015-03-02 2016-09-09 Teva Pharmaceutical Industries Ltd. Processes and intermediates for the preparation of pimavanserin
CN104961672B (zh) * 2015-05-20 2017-10-20 沈阳药科大学 一种n‑(4‑氟苄基)‑n‑(1‑甲基哌啶‑4‑基)‑n’‑(4‑异丁氧基苄基)脲的酒石酸盐的合成方法
CN104844502B (zh) * 2015-06-05 2018-07-31 齐鲁师范学院 一种匹莫范色林的制备方法
PL3325444T3 (pl) * 2015-07-20 2021-12-06 Acadia Pharmaceuticals Inc. Sposoby wytwarzania N-(4-fluorobenzylo)-N-(1-metylopiperydyn-4-ylo)-N'-(4-(2-metylopropyloksy)fenylometylo)karbamidu oraz jego soli winianowej i postaci polimorficznej C
CZ2015601A3 (cs) 2015-09-02 2017-03-15 Zentiva, K.S. Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty
CN105111135A (zh) * 2015-09-09 2015-12-02 安徽省逸欣铭医药科技有限公司 取代的尿素衍生物制备方法
CZ2015688A3 (cs) 2015-10-02 2017-04-12 Zentiva, K.S. Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jeho deuterovaných analogů
CN105153016B (zh) * 2015-10-12 2017-10-03 北京诺康达医药科技有限公司 一种匹莫范色林的制备方法
CN106588753B (zh) * 2015-10-19 2021-07-09 重庆医药工业研究院有限责任公司 一种制备匹马色林的方法
CN106699637A (zh) * 2015-11-17 2017-05-24 重庆医药工业研究院有限责任公司 一种匹马色林单酒石酸盐晶型及其制备方法
CN105924381B (zh) * 2015-12-18 2019-04-16 重庆两江药物研发中心有限公司 一种哌马色林晶型c的制备方法
CN105481757A (zh) * 2015-12-25 2016-04-13 北京康立生医药技术开发有限公司 一种哌马色林的制备方法
CN105523993A (zh) * 2015-12-28 2016-04-27 重庆两江药物研发中心有限公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲酒石酸盐晶型c及制备应用
CN107021917B (zh) * 2016-02-02 2020-08-04 江苏恩华药业股份有限公司 哌马色林半酒石酸盐的新晶型及其制备方法
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
WO2017172757A1 (en) 2016-03-29 2017-10-05 Acadia Pharmaceuticals Inc. 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
CN105820110B (zh) * 2016-05-09 2018-07-24 杭州科巢生物科技有限公司 匹莫范色林合成方法
CN109563036A (zh) 2016-05-19 2019-04-02 上海诚妙医药科技有限公司 匹莫范色林酒石酸盐的新晶型及其制备方法和用途
CN105859608B (zh) * 2016-05-27 2018-12-28 成都百裕制药股份有限公司 一种制备哌马色林半酒石酸盐晶型b的方法
HU231097B1 (hu) * 2016-07-08 2020-08-28 Egis Gyógyszergyár Zrt. Gyógyászati készítmény előállítására alkalmazható pimavanserin sók
EP3517529B1 (en) * 2016-09-23 2022-03-23 Shanghai Pharmaceuticals Holding Co., Ltd. Salt of quinazoline derivative, preparation method therefor and application thereof
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
US20180208556A1 (en) 2017-01-20 2018-07-26 Sci Pharmtech, Inc. Method for Preparing Pimavanserin
CN106916098A (zh) * 2017-03-07 2017-07-04 江苏艾立康药业股份有限公司 一种哌马色林单酒石酸盐半水合物及制备方法
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
CA3064846A1 (en) 2017-05-25 2018-11-29 Glytech, Llc Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders
CN107216271B (zh) * 2017-06-02 2018-11-13 沈阳药科大学 酒石酸匹莫范色林杂质及其制备方法
MX393950B (es) 2017-06-12 2025-03-24 Glytech Llc Composicion y metodo para el tratamiento de la depresion y psicosis en humanos
SG11202001062XA (en) * 2017-08-21 2020-03-30 Acadia Pharm Inc Compounds, salts thereof and methods for treatment of diseases
WO2019040104A2 (en) 2017-08-21 2019-02-28 Acadia Pharmaceuticals Inc. COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
JP2018035199A (ja) * 2017-12-07 2018-03-08 東和薬品株式会社 シロドシンγ型結晶及びその製造方法
WO2019120250A1 (zh) * 2017-12-22 2019-06-27 广东东阳光药业有限公司 一种哌马色林半酒石酸盐的新晶型及其制备方法
IT201800003736A1 (it) 2018-03-19 2019-09-19 Lundbeck Pharmaceuticals Italy S P A Processo per la produzione di Pimavanserin
IT201800009690A1 (it) 2018-10-23 2020-04-23 Lundbeck Pharmaceuticals Italy Spa Processo per la produzione di pimavanserina
US20220016101A1 (en) 2018-10-30 2022-01-20 Acadia Pharmaceuticals Inc. Methods of treating depression, anxiety and sexual dysfunction using the compound pimavanserin
CN111320568B (zh) * 2018-12-15 2021-12-07 浙江京新药业股份有限公司 一种匹莫范色林的新晶型及其制备方法
ES2906868T3 (es) * 2019-05-22 2022-04-20 Zakl Farmaceutyczne Polpharma S A Intermedio farmacéutico para preparar pimavanserina
US20220288048A1 (en) 2019-07-22 2022-09-15 Acadia Pharmaceuticals Inc. Pimavanserin for treating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
US20220323429A1 (en) 2019-08-15 2022-10-13 Acadia Pharmaceuticals Inc. Pimavanserin for treating neurodegenerative diseases
CN114867473A (zh) 2019-11-08 2022-08-05 凯莫森特里克斯股份有限公司 补体成分c5a受体的盐形式
US11603356B2 (en) * 2019-11-08 2023-03-14 Chemocentryx, Inc. Amorphous form of a complement component C5a receptor
JP2022554019A (ja) 2019-11-08 2022-12-27 ケモセントリックス，インコーポレイティド 補体成分Ｃ５ａ受容体の遊離塩基結晶形態
CN113214231B (zh) * 2020-01-21 2022-04-08 瀚远医药有限公司 5ht2a受体拮抗剂及其医疗应用
WO2022094230A1 (en) 2020-11-02 2022-05-05 Acadia Pharmaceuticals Inc. Compounds for treating psychosis or depression
CN112920108A (zh) * 2021-01-29 2021-06-08 北京诺康达医药科技股份有限公司 酒石酸匹莫范色林晶型a的制备方法
CN114874103B (zh) * 2022-05-11 2024-09-06 合肥立方制药股份有限公司 一种匹莫范色林中间体4-异丁氧基苄胺的连续合成方法
JP7406285B1 (ja) 2023-03-09 2023-12-27 国立大学法人島根大学 ビリルビン誘発性神経機能障害、黄疸を伴う精神疾患、又はビリルビンｕｄｐ－グルクロン酸転移酵素遺伝子変異に起因する精神疾患を治療、予防又は管理するための医薬組成物

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794333A (fr) 1972-01-20 1973-07-19 Wyeth John & Brother Ltd Composes heterocycliques azotes therapeutiques
GB1507462A (en) * 1974-03-21 1978-04-12 Gallardo Antonio Sa N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US3983234A (en) * 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
GB1586468A (en) 1976-10-29 1981-03-18 Anphar Sa Piperidine derivatives
CA1140119A (en) 1978-04-03 1983-01-25 Joseph Torremans N-heterocyclyl-4-piperidinamines
US4255432A (en) * 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
US4332804A (en) * 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US4353901A (en) 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones
GB8527052D0 (en) 1985-11-02 1985-12-04 Beecham Group Plc Compounds
GB8621892D0 (en) 1986-09-11 1986-10-15 Lundbeck & Co As H Organic compound
FR2642069B1 (fr) * 1989-01-20 1991-04-12 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
US5214055A (en) * 1990-05-18 1993-05-25 Adir Et Compagnie Aminopiperidine 4-oxo-4H-chromen-2-yl compounds
US5216165A (en) 1990-10-03 1993-06-01 American Home Products Corporation N-substituted aminoquinolines as analgesic agents
IT1252227B (it) 1991-12-17 1995-06-05 Ciba Geigy Spa Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
JPH09501404A (ja) 1993-05-26 1997-02-10 スミスクライン・ビーチャム・ラボラトワール・ファルマソーティク 新規化合物
IL110298A (en) 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
DE4404183A1 (de) 1994-02-10 1995-08-17 Merck Patent Gmbh 4-Amino-1-piperidylbenzoylguanidine
US5795894A (en) * 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
WO1997011940A1 (en) 1995-09-29 1997-04-03 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
EP0944388A4 (en) 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
EP0960104B1 (en) 1996-04-17 2004-06-16 Bristol-Myers Squibb Pharma Company N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors
US5869488A (en) 1996-05-01 1999-02-09 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5877173A (en) 1996-08-28 1999-03-02 Washington University Preventing neuronal degeneration in Alzheimer's disease
SK285631B6 (sk) 1996-09-10 2007-05-03 Dr. Karl Thomae Gmbh Modifikované aminokyseliny, farmaceutický prostriedok s ich obsahom a ich použitie
DE19643331A1 (de) 1996-10-21 1998-04-23 Thomae Gmbh Dr K 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
TR199902752T2 (xx) 1997-05-08 2000-06-21 Smithkline Beecham Corporation Proteaz inhibit�rleri.
CA2291734A1 (en) * 1997-06-27 1999-01-07 Merck Sharp & Dohme Limited Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
US20020163987A1 (en) * 1997-12-12 2002-11-07 British Nuclear Fuels Plc Monitoring a sample containing a neutron source
US6107324A (en) * 1998-04-14 2000-08-22 Arena Pharmaceuticals Inc. 5-HT2A receptor inverse agonists
US6140509A (en) 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6358698B1 (en) 1998-10-07 2002-03-19 Acadia Pharmacueticals Inc. Methods of identifying inverse agonists of the serotonin 2A receptor
CA2315050C (en) 1998-10-16 2009-02-03 Suntory Limited Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof
US6150393A (en) 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
JP2002539260A (ja) 1999-03-24 2002-11-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アスパルチルプロテアーゼインヒビターを使用して神経変性障害を処置する方法
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
DE60023492T2 (de) 1999-05-17 2006-07-20 Novo Nordisk A/S Glucagon antagonisten/inverse agonisten
US20050148018A1 (en) * 1999-10-07 2005-07-07 David Weiner Methods of identifying inverse agonists of the serotonin 2A receptor
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
US7022698B2 (en) * 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
RU2002126554A (ru) * 2000-03-06 2004-03-20 Акадиа Фармасьютикалз, Инк. (Us) Азациклические соединения для применения при лечении опосредованных серотонином заболеваний
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
GB0108099D0 (en) 2001-03-30 2001-05-23 Hoffmann La Roche Aminopiperidine derivatives
EP1402871B1 (en) * 2001-06-05 2009-02-18 Toyo Boseki Kabushiki Kaisha Antithrombotic compositions and medical instruments containing the same
WO2003057698A2 (en) * 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Spiroazacyclic compounds as monoamine receptor modulators
KR20040075353A (ko) 2002-01-17 2004-08-27 제너럴 일렉트릭 캄파니 양이온성 개시제로서 약하게 배위된 이미다졸리딘음이온을 포함하는 오늄 염
EP1509505A2 (en) 2002-01-23 2005-03-02 Arena Pharmaceuticals, Inc. SMALL MOLECULE MODULATORS OF THE 5−HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
CN100509804C (zh) 2002-06-24 2009-07-08 阿卡蒂亚药品公司 N-取代哌啶衍生物作为血清素受体试剂
WO2004009549A2 (en) 2002-07-18 2004-01-29 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
AU2003284899A1 (en) 2002-10-29 2004-05-25 Miicro, Inc. Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
PT1587789E (pt) * 2003-01-16 2008-12-16 Acadia Pharm Inc Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas
JP2006515628A (ja) * 2003-01-23 2006-06-01 アカディア ファーマシューティカルズ，インコーポレーテッド ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用
SI1594840T1 (sl) 2003-02-17 2006-12-31 Hoffmann La Roche Derivati piperidin-benzensulfonamida
US7628762B2 (en) 2003-03-19 2009-12-08 Suros Surgical Systems, Inc. Adapter assembly for stereotactic biopsy
PT1696931E (pt) * 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
US7820695B2 (en) * 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
JP4996467B2 (ja) * 2004-09-27 2012-08-08 アカディア ファーマシューティカルズ インコーポレイテッド Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成
US7790899B2 (en) * 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms

Also Published As

Publication number Publication date
JP4996467B2 (ja) 2012-08-08
US7923564B2 (en) 2011-04-12
US7732615B2 (en) 2010-06-08
MX2007003403A (es) 2007-05-07
NZ553702A (en) 2010-10-29
RU2417986C2 (ru) 2011-05-10
ES2412207T3 (es) 2013-07-10
CN102153505B (zh) 2014-10-22
ZA201000714B (en) 2010-10-27
US20060205780A1 (en) 2006-09-14
KR20070083799A (ko) 2007-08-24
US7868176B2 (en) 2011-01-11
EP1794126B1 (en) 2013-03-20
SG157378A1 (en) 2009-12-29
JP2008514642A (ja) 2008-05-08
JP5154227B2 (ja) 2013-02-27
WO2006036874A1 (en) 2006-04-06
ZA200702345B (en) 2010-04-28
WO2006037043A1 (en) 2006-04-06
ES2530258T3 (es) 2015-02-27
PL2289879T3 (pl) 2015-05-29
US20110184179A1 (en) 2011-07-28
KR20070083800A (ko) 2007-08-24
PL1794126T3 (pl) 2013-08-30
CN101031548A (zh) 2007-09-05
HK1102397A1 (en) 2007-11-16
CA2580129A1 (en) 2006-04-06
AU2005289635A1 (en) 2006-04-06
SG161221A1 (en) 2010-05-27
AU2005289444A1 (en) 2006-04-06
CN102153505A (zh) 2011-08-17
AU2005289444A2 (en) 2006-04-06
CA2580136A1 (en) 2006-04-06
CA2580136C (en) 2015-08-18
US20100305329A1 (en) 2010-12-02
RU2007115921A (ru) 2008-11-10
EP1794125A1 (en) 2007-06-13
EP2289879B1 (en) 2014-11-12
RU2007115886A (ru) 2008-11-10
JP2008514627A (ja) 2008-05-08
AU2005289635A2 (en) 2006-04-06
RU2387643C2 (ru) 2010-04-27
US20060205781A1 (en) 2006-09-14
KR101260036B1 (ko) 2013-05-06
EP2289879A1 (en) 2011-03-02
CN101035759B (zh) 2011-06-15
US20060106063A1 (en) 2006-05-18
AU2005289444B2 (en) 2012-06-14
ZA200702349B (en) 2008-10-29
DK1794126T3 (da) 2013-06-24
BRPI0516063A (pt) 2008-08-19
US20060111399A1 (en) 2006-05-25
US8236960B2 (en) 2012-08-07
CN101035759A (zh) 2007-09-12
CN101031548B (zh) 2011-04-06
EP1794126A1 (en) 2007-06-13

Similar Documents

Publication Publication Date Title
MX2007003433A (es) Sintesis de n-fluorobencil) -n- (1-metilpiperidin-4-il) -n'- (4- (2-metilpropiloxi) fenilmetil) carbamida y su sal de tartrato y formas cristalinas.
WO2008144326A3 (en) Synthesis of n-(4-fluorobenzyl)-n-(l-methylpiperidin-4-yl)-n'-(4- (2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
MY136883A (en) 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
RU2436776C2 (ru) ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
NO20070606L (no) Inhibitorer av IAP
NO20073663L (no) Tiazol-4-karboksamid-derivater som mGluR5 antagonister
PE20061366A1 (es) Compuestos y composiciones como inhibidores de quinasa de proteina
EA200901514A1 (ru) Новая сольватная и кристаллическая форма производных карбамоилциклогексана
ATE401066T1 (de) Methoden zur behandlung der essstörungen
TW200609204A (en) Sulfonamide derivatives, preparation thereof and therapeutic application thereof
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20063486L (no) Bicykloesterderivater
MY136800A (en) Inhibitors of the interaction between mdm2 and p53
NO20083114L (no) Polysykliske indazolderivater som er ERK-inhibitorer
NO20055714L (no) Inhibitorer av fosfatidylinositol 3-kinase
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
TW200633703A (en) Salts of n-[2-({3R)-1-[trans-4-hydroxy-4-(6-methoxypyridin-3-yl)-cyclohexyl]pyrrolidin-3-yl}amino)-2-oxoethyl]-3-(trifluoromethyl)benzamide
NO964533L (no) Nye kinolon 5-(N-heterosubstituert amino) antimikrobielle forbindelser
SE0403171D0 (sv) New compounds
TNSN06203A1 (en) Derivatives of n- (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
NO20084674L (no) 1- [ (4-(benzoyl (metyl) amino] -3- (fenyl) butyl] azetidinderivater for behandling av gastrointestinale lidelser
NO20060314L (no) Nicotinamid-derivater anvendbare som PDE4-inhibitorer
NO20074622L (no) Metabolitter for NK-1 antagonister for brekninger

Legal Events

Date Code Title Description
FG Grant or registration